Raymond James Financial Inc. Acquires 28,430 Shares of Vaxcyte, Inc. $PCVX

Key Points

• Raymond James Financial Inc. has increased its stake in Vaxcyte, Inc. by 10.7%, now owning approximately 0.23% of the company's shares valued at $11.1 million.
• Wall Street analysts are optimistic about Vaxcyte, with a consensus Buy rating and an average target price of $136.50.
• Vaxcyte reported a loss of ($1.22) EPS for the last quarter, missing the consensus estimate of ($1.12) by ($0.10).

Raymond James Financial Inc. raised its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 10.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 293,134 shares of the company's stock after purchasing an additional 28,430 shares during the period. Raymond James Financial Inc. owned 0.23% of Vaxcyte worth $11,069,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the company. Bridgefront Capital LLC grew its stake in shares of Vaxcyte by 4.2% in the 4th quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock valued at $347,000 after buying an additional 172 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Vaxcyte by 10.9% during the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock worth $112,000 after purchasing an additional 293 shares during the last quarter. Avior Wealth Management LLC boosted its holdings in Vaxcyte by 5.3% in the first quarter. Avior Wealth Management LLC now owns 6,799 shares of the company's stock valued at $257,000 after acquiring an additional 343 shares during the last quarter. US Bancorp DE lifted its stake in shares of Vaxcyte by 7.2% during the first quarter. US Bancorp DE now owns 5,344 shares of the company's stock worth $202,000 after purchasing an additional 357 shares in the last quarter. Finally, Xponance Inc. increased its holdings in Vaxcyte by 4.7% in the first quarter. Xponance Inc. now owns 9,320 shares of the company's stock valued at $352,000 after buying an additional 415 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX traded up $0.67 during midday trading on Friday, reaching $32.82. 260,879 shares of the company traded hands, compared to its average volume of 1,752,484. The firm has a market cap of $4.26 billion, a PE ratio of -8.01 and a beta of 1.04. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06. The stock's 50-day simple moving average is $33.21 and its 200-day simple moving average is $41.31.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter in the prior year, the business earned ($1.10) earnings per share. On average, equities research analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Analyst Ratings Changes

Separately, Cowen reiterated a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. Based on data from MarketBeat, Vaxcyte presently has an average rating of "Buy" and an average price target of $130.00.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.